Interim-PET predicts progression-free survival in stage IV Hodgkin lymphoma treated with upfront brentuximab vedotin-AVD

被引：0

作者：

Rusconi, Chiara ^{[1
]}

Barone, Angelica ^{[2
]}

Visentin, Andrea ^{[3
]}

Bianchi, Benedetta ^{[4
]}

Zilioli, Vittorio Ruggero ^{[5
]}

Bernardelli, Andrea ^{[6
]}

Iadecola, Sara ^{[7
]}

Olivari, Edoardo ^{[2
]}

Rossi, Francesca Gaia ^{[8
]}

Gotti, Manuel ^{[9
,10
]}

Cecchetti, Caterina ^{[11
]}

Puccini, Benedetta ^{[12
]}

Franceschetti, Silvia ^{[13
]}

Molteni, Alfredo ^{[14
]}

Steffanoni, Sara ^{[15
]}

Marino, Fabrizio ^{[16
]}

Vanazzi, Anna ^{[17
]}

Guidetti, Anna ^{[1
,2
]}

Merli, Michele ^{[8
]}

Mazzon, Federico ^{[2
]}

Marchetti, Alfredo ^{[2
]}

Cellini, Alessandro ^{[3
]}

Muzi, Cristina ^{[5
]}

Miceli, Rosalba ^{[7
]}

Visco, Carlo ^{[6
]}

Re, Alessandro ^{[18
]}

Corradini, Paolo ^{[1
,2
]}

机构：

[1] Fdn IRCCS Ist Nazl Tumori Milano, Div Hematol & Stem Cell Transplantat, Milan, Italy

[2] Univ Milan, Sch Med, Milan, Italy

[3] Azienda Osped Univ Padova, UOC Patol Cardiovasc, Padua, Italy

[4] Univ Insubria, Univ Hosp Osped Circolo & Fdn Macchi, Osped Circolo & Fdn Macchi ASST Sette Laghi, Hematol, Varese, Italy

[5] ASST Grande Osped Metropolitano Niguarda, Div Hematol, Milan, Italy

[6] Univ Verona, Dept Engn Innovat Med, Sect Hematol, Verona, Italy

[7] Fdn IRCCS Ist Nazl Tumori Milano, Biostat Clin Res Unit, Milan, Italy

[8] Fdn IRCCS Ca Granda Osped Maggiore Policlin Milano, Milan, Italy

[9] Univ Pavia, Dept Mol Med, Pavia, Italy

[10] Fdn IRCCS Policlin San Matteo, Div Hematol, Pavia, Italy

[11] ASST Valle Olona, Osped Circolo Busto Arsizio, SC Ematol, Busto Arsizio, Italy

[12] Careggi Univ Hosp, Hematol Unit, Florence, Italy

[13] ASST Ovest Milanese, Osped Legnano, UOC Ematol, Legnano, Italy

[14] ASST Ist Ospitalieri, UOC Ematol, Cremona, Italy

[15] Osped Valduce, UO Gastroenterol, Como, Italy

[16] IRCCS San Raffaele Sci Inst, Lymphoma Unit, Milan, Italy

[17] European Inst Oncol IRCCS, Oncohematol Div, IEO, Milan, Italy

[18] Spedali Civili Brescia, Lymphoma Unit, Hematol, Brescia, Italy

来源：

LEUKEMIA & LYMPHOMA | 2025年 / 66卷 / 05期

关键词：

Interim PET; Hodgkin lymphoma; brentuximab vedotin-AVD; POSITRON-EMISSION-TOMOGRAPHY; OPEN-LABEL; RESPONSE ASSESSMENT; PROGNOSTIC SCORE; FOLLOW-UP; CHEMOTHERAPY; DISEASE; SCAN; ABVD; BEACOPP;

D O I：

10.1080/10428194.2024.2446609

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Brentuximab vedotin (BV) plus doxorubicin, vinblastine and dacarbazine (AVD) demonstrated to improve survival compared to ABVD as frontline treatment of advanced stage Hodgkin Lymphoma (HL). We retrospectively collected data of 99 stage IV HL patients treated off-protocol with BV-AVD to evaluate the predictive role of interim-PET. Median age was 36 years (range: 18-82); 83.8% patients completed all planned 6 cycles and 80.8% obtained complete response at PET6. Median follow-up was 14.4 months; 1-year progression-free survival (PFS) and overall survival were 84.1% (CI 95%: 77-91.9) and 96.9% (CI 95%: 93.6-100). PET2-negative patients had a superior 1-year PFS compared to PET2-positive patients: 90.0% vs 46.2% (p < .001). At multivariable analysis, PET2 positivity retained unfavorable statistical significance in PFS: HR 4.6 (95% CI: 1.4-15.2, p = .009). BV-AVD was confirmed to be effective in a real-world setting, while PET2-positive patients displayed a remarkably lower 1-year PFS than that previously reported and might benefit from a PET-driven approach.

引用

页码：879 / 887

页数：9

共 32 条

[1]

Adcetris, 2023, EPAR MED OVERVIEW RE

[2]

[Anonymous], 2009, Common Terminology Criteria for Adverse Events (CTCAE)

[3]

[Anonymous], 2021, DETERMINA AIFA N 103

[4] Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management [J].

Ansell, Stephen M. .

AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (11) :1478-1488

[5] Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma [J].

Ansell, Stephen M. ;

Radford, John ;

Connors, Joseph M. ;

Dlugosz-Danecka, Monika ;

Kim, Won-Seog ;

Gallamini, Andrea ;

Ramchandren, Radhakrishnan ;

Friedberg, Jonathan W. ;

Advani, Ranjana ;

Hutchings, Martin ;

Evens, Andrew M. ;

Smolewski, Piotr ;

Savage, Kerry J. ;

Bartlett, Nancy L. ;

Eom, Hyeon-Seok ;

Abramson, Jeremy S. ;

Dong, Cassie ;

Campana, Frank ;

Fenton, Keenan ;

Puhlmann, Markus ;

Straus, David J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (04) :310-320

[6] Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group [J].

Barrington, Sally F. ;

Mikhaeel, N. George ;

Kostakoglu, Lale ;

Meignan, Michel ;

Hutchings, Martin ;

Mueeller, Stefan P. ;

Schwartz, Lawrence H. ;

Zucca, Emanuele ;

Fisher, Richard I. ;

Trotman, Judith ;

Hoekstra, Otto S. ;

Hicks, Rodney J. ;

O'Doherty, Michael J. ;

Hustinx, Roland ;

Biggi, Alberto ;

Cheson, Bruce D. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :3048-+

[7] ALTERNATING NON-CROSS-RESISTANT COMBINATION CHEMOTHERAPY OR MOPP IN STAGE-IV HODGKINS-DISEASE - A REPORT OF 8-YEAR RESULTS [J].

BONADONNA, G ;

VALAGUSSA, P ;

SANTORO, A .

ANNALS OF INTERNAL MEDICINE, 1986, 104 (06) :739-746

[8] Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial [J].

Borchmann, Peter ;

Ferdinandus, Justin ;

Schneider, Gundolf ;

Moccia, Alden ;

Greil, Richard ;

Hertzberg, Mark ;

Schaub, Valdete ;

Huettmann, Andreas ;

Keil, Felix ;

Dierlamm, Judith ;

Haenel, Mathias ;

Novak, Urban ;

Meissner, Julia ;

Zimmermann, Andreas ;

Mathas, Stephan ;

Zijlstra, Josee M. ;

Fossa, Alexander ;

Viardot, Andreas ;

Hertenstein, Bernd ;

Martin, Sonja ;

Giri, Pratyush ;

Scholl, Sebastian ;

Topp, Maxs ;

Jung, Wolfram ;

Vucinic, Vladan ;

Beck, Hans-Joachim ;

Kerkhoff, Andrea ;

Unger, Benjamin ;

Rank, Andreas ;

Schroers, Roland ;

Bueschenfelde, Christian Meyer zum ;

de Wit, Maike ;

Trautmann-Grill, Karolin ;

Kamper, Peter ;

Molin, Daniel ;

Kreissl, Stefanie ;

Kaul, Helen ;

von Tresckow, Bastian ;

Borchmann, Sven ;

Behringer, Karolin ;

Fuchs, Michael ;

Rosenwald, Andreas ;

Klapper, Wolfram ;

Eich, Hans-Theodor ;

Baues, Christian ;

Zomas, Athanasios ;

Hallek, Michael ;

Dietlein, Markus ;

Kobe, Carsten ;

Diehl, Volker .

LANCET, 2024, 404 (10450) :341-352

[9] PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group [J].

Borchmann, Peter ;

Goergen, Helen ;

Kobe, Carsten ;

Lohri, Andreas ;

Greil, Richard ;

Eichenauer, Dennis A. ;

Zijlstra, Josee M. ;

Markova, Jana ;

Meissner, Julia ;

Feuring-Buske, Michaela ;

Huttmann, Andreas ;

Dierlamm, Judith ;

Soekler, Martin ;

Beck, Hans-Joachim ;

Willenbacher, Wolfgang ;

Ludwig, Wolf-Dieter ;

Pabst, Thomas ;

Topp, Max S. ;

Hitz, Felicitas ;

Bentz, Martin ;

Keller, Ulrich Bernd ;

Kuhnhardt, Dagmar ;

Ostermann, Helmut ;

Schmitz, Norbert ;

Hertenstein, Bernd ;

Aulitzky, Walter ;

Maschmeyer, Georg ;

Vieler, Tom ;

Eich, Hans ;

Baues, Christian ;

Stein, Harald ;

Fuchs, Michael ;

Kuhnert, Georg ;

Diehl, Volker ;

Dietlein, Markus ;

Engert, Andreas .

LANCET, 2017, 390 (10114) :2790-2802

[10] Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort [J].

Bowers, Jackson T. ;

Anna, Jacob ;

Bair, Steven M. ;

Annunzio, Kaitlin ;

Epperla, Narendranath ;

Pullukkara, Jerrin Joy ;

Gaballa, Sameh ;

Spinner, Michael A. ;

Li, Shuning ;

Messmer, Marcus R. ;

Nguyen, Joseph ;

Ayers, Emily C. ;

Wagner, Charlotte B. ;

Hu, Boyu ;

Di, Mengyang ;

Huntington, Scott F. ;

Furqan, Fateeha ;

Shah, Nirav N. ;

Chen, Christina ;

Ballard, Hatcher J. ;

Hughes, Mitchell E. ;

Chong, Elise A. ;

Nasta, Sunita D. ;

Barta, Stefan K. ;

Landsburg, Daniel J. ;

Svoboda, Jakub .

BLOOD ADVANCES, 2023, 7 (21) :6630-6638

← 1 2 3 4 →